We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Biosensing Technology Breakthrough Paves Way for New Methods of Early Disease Detection

By LabMedica International staff writers
Posted on 11 Dec 2024

Nanopores are tiny openings that can detect individual molecules as they pass through, making them ideal for analyzing biomolecules like DNA and proteins. More...

However, detecting proteins at extremely low concentrations—such as those found in the early stages of diseases—has been challenging. Now, a new breakthrough in nanotechnology for biomolecule detection and analysis could open doors to more effective early disease detection methods.

In a study conducted at SMU Lyle (Dallas, TX, USA) and featured on the cover of Analytical Chemistry, researchers combined octahedral DNA origami structures with solid-state nanopores to enhance the detection of proteins, particularly those present in low concentrations. The researchers found that integrating DNA origami's precision with the strength of solid-state nanopores results in a "hybrid nanopore" system, offering more accurate and sensitive protein detection. DNA origami is a technique in which DNA strands are folded into specific shapes, such as an octahedron, to improve the nanopore’s capacity to capture and detect proteins. In their study, the researchers used holo human serum transferrin as a model protein, demonstrating that this hybrid nanopore system outperformed traditional nanopores in both sensitivity and detection accuracy.

Many diseases, including cancer and neurodegenerative disorders, are marked by proteins present in very small quantities, making them difficult to detect in the early stages. The hybrid nanopore's ability to detect these low-abundance proteins could lead to earlier diagnoses and more effective treatment outcomes. Moving forward, the research team plans to refine the DNA origami structure and nanopore configurations to further improve sensitivity and expand the range of detectable biomolecules. This innovative approach could revolutionize fields like drug discovery, disease diagnostics, and fundamental biological research.

“This work could pave the way for developing advanced biosensing technologies, with potential applications in biomedical research and diagnostic tools – especially for diseases marked by low-abundance protein biomarkers,” said SMU Lyle mechanical engineering graduate student Kamruzzaman Joty.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Automatic CLIA Analyzer
Shine i6000
New
Gastrointestinal Panel
Xpert® GI Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image Credit: Adobe Stock

Machine Learning Cytology Tool Improves Cancer Cell Identification

Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.